News | September 18, 2025
Bayer inaugurates new phytomedicines lab facility
The lab will facilitate the development of herbal and natural-based solutions
The lab will facilitate the development of herbal and natural-based solutions
Skyhawk Therapeutics enters into an option agreement to grant Merck KGaA, Darmstadt, Germany, exclusive global rights to drug candidates pursued under the collaboration upon option exercise
Prof. Götz is Director of the Institute of Stem Cell Research at Helmholtz Center Munich and Chair of Physiological Genomics at Ludwig-Maximilians-Universität, Munich
Reinforces position as first commercially approved contract development and manufacturing organization (CDMO) for ADCs in North America
Investment in new plant meets increasing demand for functional excipients for oral drug delivery
MyClad is a global Phase III study evaluating the efficacy and safety of cladribine capsules for the treatment of generalized Myasthenia Gravis (gMG)
The new facility will accelerate the biotech and pharmaceutical industry's development by manufacturing vaccines, cell and gene therapies, and protein-based therapies
Acquisition will advance Merck’s integrated offering for viral vector manufacturing
New solvent-free micronization technology expanded at the Darmstadt site in Germany
The collaboration focuses on the development and sharing of Standard Quality and Regulatory Documentation (StaQRD), a standard guide for the electronic transfer of information
Subscribe To Our Newsletter & Stay Updated
